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Since the reformation of the National Health Insurance
Act in 2000, the Health Insurance Review and
Assessment Service (HIRA) in the Republic of Korea
has performed quality assessments for healthcare
providers. Under the single unified National Health
Insurance system, the HIRA quality assessments have
progressed rapidly due to advanced technologies in
information collection and communication. 
Information regarding the performance of individual
institutions is made accessible to the public and each
provider. The HIRA quality assessments include a
number of measures to help all nationwide healthcare
institutions improve the quality of care and lower costs.
HIRA includes 16 items (2011) as follows: acute
myocardial infarction, acute stroke, use of prophylactic
antibiotics for surgery (11 surgeries), Caesarian section,
surgical volume indicator, coronary artery bypass graft,
prescription (6 sub-measures), hypertension, diabetes
mellitus, long-term care hospitals, mental hospital within
medical aid, hemodialysis, otitis media in children,
colorectal cancer, gastric cancer, and breast cancer.
More than 36% of all National Health Insurance
medical expenses are evaluated by HIRA quality
assessment. The Reformed National Health Insurance
Act of 2000 authorized a financial incentive structure
that could adjust the payment by increasing or reducing
the cost of the medical care benefit in accordance with
performance. Previously, the government postponed
the financial incentive because providers, administrators,
and patients were not experienced in the HIRA quality
assessment. However, the need to implement financial
incentives for performance emerged after the mid-
2000s, and the Board of Audit and Inspection and the
National Assembly recommended the implementation
of pay for performance. The Ministry of Health and
Welfare (MOHW) allowed financial incentives for
performance to be adopted and allowed HIRA to
implement the Value Incentive Program (VIP).
Currently, VIPs are under expansion for primary
clinics, hospitals, and nursing facilities. This article
documents the experience of the VIP for acute-phase
hospitals.
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Since the reformation of the National Health Insurance Act in 2000, the Health Insurance Review and Assessment Service
(HIRA) in the Republic of Korea has performed quality assessments for healthcare providers. The HIRA Value Incentive
Program (VIP), established in July 2007, provides incentives for excellent-quality institutions and disincentives for poor-
quality ones. The program is implemented based on data collected between July 2007 and December 2009. The goal of
the VIP is to improve the overall quality of care and decrease the quality gaps among healthcare institutions. Thus far, the
VIP has targeted acute myocardial infarction (AMI) and Caesarian section (C-section) care. The incentives and
disincentives awarded to the hospitals by their composite quality scores of the AMI and C-section scores. The results of
the VIP showed continuous and marked improvement in the composite quality scores of the AMI and C-section measures
between 2007 and 2010. With the demonstrated success of the VIP project, the Ministry of Health and Welfare expanded
the program in 2011 to include general hospitals. The HIRA VIP was deemed applicable to the Korean healthcare system,
but before it can be expanded further, the program must overcome several major concerns, as follows: inclusion of
resource use measures, rigorous evaluation of impact, application of the VIP to the changing payment system, and
expansion of the VIP to primary care clinics.
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I. History 
The VIP, established in July 2007, provides incentives
for excellent-quality institutions and disincentives for
poor-quality ones [1,2]. The program was implemented
based on data collected between July 2007 and
December 2009. During this period, tertiary hospitals
were evaluated for their rates of acute myocardial
infarction (AMI) and Caesarean section (C-section). The
results were announced based on these data, and the
incentives were provided in the following year. Hence, a
1-year time lag exists between each period reflecting the
clinical treatment performed and the reporting of the
results. 
The expanded VIP was launched in 2010. Data
collection started in January 2010 and will continue
until December 2012. Target institutions have been
expanded to general hospitals, and target groups of
incentives (and disincentives) have also been extended.
The first results of the expanded VIP were announced in
November 2011 and incentives were provided in
December 2011.
II. Goal 
The goal of the VIP is to improve the overall quality
of care and decrease the quality gaps among healthcare
institutions. Thus far, the VIP has targeted AMI and C-
section care. The 30-day case fatality of AMI in Korea
(6.3%) is the highest among the member countries of the
Organization for Economic Cooperation and
Development (OECD, average rate across OECD
countries was 5.4% in 2009) [3]. The C-section rate in
Korea (35.1%) is also among the highest levels of the
OECD member countries (average rate across OECD
countries was 25.8% in 2008) [3].
III. Target Hospitals
Forty-four tertiary hospitals have thus far been
mandated to participate in the VIP for the following
reasons. First, many of them already have mechanisms
of quality assessment and experience with quality
improvement. Second, they are expected to practice
social accountability in terms of quality. Hospitals that
are designated as tertiary hospitals are provided with an
additional payment amounting to 30% of the total
payment within the National Health Insurance.  
IV. Quality Measures
To evaluate the quality of AMI care, the VIP has
assessed six indicators to date: 1) the rate of
thrombolytic drug administration within 60 minutes of
hospital arrival; 2) the rate of primary percutaneous
coronary intervention (PCI) performance within 120
minutes of arrival; 3) the rate of aspirin administration
upon arrival (as a percentage of all arrival patients); 4)
the rate of aspirin prescription at discharge (as a
percentage of all discharge patients); 5) the rate of beta-
blocker prescription at discharge (as a percentage of all
discharge patients); and 6) the 30-day case fatality after
hospitalization [4-10]. After measuring these six
indicators, a composite quality score (CQS) is calculated
for each hospital (Figure 1 shows the CQSs for VIP and
expanded VIP). The rates of thrombolytic drug
Figure 1. Calculation of Value Incentive Program’s
composite quality score.
AMI, acute myocardial infarction; PCI, percutaneous coronary intervention;
C-section, Caesarian section.
AMI composite quality score
Process measures
C-section rate quality score
15 clinical risk factors
C-section rate quality score = (O - E) / SE
O, observed C-section rate; E, expected C-section rate (based on 15 clinical risk
factors); SE, standard error.
- Maternal factors: preeclampsia and eclampsia, bleeding, diabetes mellitus, age,
venereal disease, gynecologic malignancy, placenta previa, placenta abruption,
dystocia
- Neonatal factors: macrosomia, multiple gestation, cord prolapsed and vasa
previa, fetal abnormality, malpresentation
- Other: previous C-section, premature birth
Weight Denominator Numerator
Fibrinolytic therapy
received within 60 min of
arrival
Primary PCI received
within 120 min of hospital
arrival
Reperfusion group (A) =
(N1+N2)/(D1+D2)
Aspirin at arrival
Aspirin prescribed at
discharge
Beta-blocker prescribed at
discharge
Medication group (B) =
(N3+N4+N5)/(D3+D4+D5)
Outcome measure
Adjusted 30-day mortality
rate: survival index (C)
Composite quality score = {[(A4.5)+(B2.5)+(C3.0)] /10}100
N1
N2
N1+N2
N3
N4
N5
N3+N4+N5
D2
D1+D2 4.5
D3
D4
D5
D3+D4+D5 2.5
3.0
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administration and primary PCI performance were
incorporated into the reperfusion indicators, and the rates
of aspirin prescription at arrival and discharge and the
rate of beta-blocker prescription were merged into the
drug prescription rate. To produce the composite score, a
relative weight was given to three indicators: 4.5 for
reperfusion, 2.5 for drug prescription, and 3.0 for case
fatality rate. In 2010, the thresholds of first and second
measures of AMI were shortened from 60 minutes and
120 minutes to 30 minutes and 90 minustes.
The quality of the C-section rate was assessed by the
quality score, which is the difference between the
observed and expected C-section rates (Figure 1) [11-
16]. The expected C-section rate was calculated by a
multiple regression equation with 16 risk factors of C-
section. Bleeding was excluded, and a total of 15 risk
factors were used from 2010 (expanded VIP).
Institutions are excluded when their total number of
cases comes to less than 30, or when each indicator
comprises fewer than 10 cases in AMI CQS.
The information needed for AMI quality assessment was
gathered from the claims data warehouse and a Web-based
hospital quality data acquisition system, while the C-section
rate was calculated only with the claims data warehouse.
Using an independent survey, the validity of the data was
investigated. Institutions are excluded when their total
number of cases comes to less than 30 in C-section CQS.
There are four steps from the development to
utilization of the measures. The first step leads to
developing a plan for the included items, institutions,
periods, inclusion/exclusion criteria, and utilization of
results. The next step is to formulate a detailed plan for
each item, and when medical advice is required, it can be
collected by an expert consultative body. The third step
is to execute the assessment plan including data
collection, analysis, etc. The last step is to disclose the
assessment results and pay for performance (e.g., VIP).
The central assessment committee, which was
established by Article 59 of the National Health
Insurance Act, reviews each step of the assessment
implementation procedures.
V. Applying Incentives
The VIP was designed after the Premier Hospital
Quality Incentive Demonstration Project of the United
States Centers for Medicare and Medicaid Services
(Figure 2). The hospitals were categorized into five
performance grades by the composite quality scores of
the AMI and C-section scores. In the first year, the
performance grade of each hospital was reported to the
public, but the incentive or penalty was not applied. The
upper limit of the fifth-ranked group in the first year was
announced as the threshold of the penalty 2 years later. If
a hospital attained a quality score lower than this
threshold 2 years later, the penalty would be applied. The
incentive and the penalty were 1% of the cost paid by the
National Health Insurance Corporation. In the second
year, the 1% incentive was provided to the top performers
and those that improved their quality of care. In the third
year, the 1% penalty would have been applied to any
hospitals that performed lower that the threshold.
Figure 2. Model of the Value Incentive Program in Korea.,PSFBO7BMVF*ODFOUJWF1SPHSBN
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However, each hospital scored higher than the threshold
level so none were penalized. An incentive was given to
all hospitals, some for being high performers and others
for improving their quality of care. 
VI. Amount of Incentives
The incentives awarded to the hospitals were Korean
won (KRW) 857 million in total between 2008 and
2010. In the second year, KRW 453 million was
provided to 21 hospitals, and in the third year KRW 404
million was awarded to 26 hospitals (Table 1). Because
the overall quality scores improved, a penalty was not
applied to any hospital. 
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I. Acute Myocardial Infarction 
The results of the VIP and expanded VIP showed
continuous and marked improvement in the CQSs of the
AMI measures between 2007 and 2010. There was a
5.60-point increase in the mean CQS and 6.72 decrease
in the standard deviation (or variation in performance)
among institutions. 
There were clear improvements in the process
indicators, including the fibrinolytic administration rate
within 60 minutes of hospital arrival and primary PCI
rate within 120 minutes of hospital arrival. These
results show that the margin for improvement was
actually quite low because the hospitals already had
high rates of aspirin administration at arrival, aspirin
prescription at discharge, and beta-blocker prescription
at discharge.
Figure 3. Improvement in composite quality scores of acute myocardial infarction care by year.
Table 1. Payment status of incentives and disincentives
Unit: institution, 10000 Korean won.
AMI, acute myocardial infarction; C-section, Caesarian section.
1 First grade and quality-improved institutions.
2 Number of overlapped institutions: nine institutions for the second year (first
grade for both items: five institutions, first grade or quality-improved: four
institutions); four institutions for the third year (first grade for both items: one
institution, quality-improved in both items: one institution, first grade or quality-
improved: two institutions).
3 Institutions under the disincentive threshold.
3rd year
(treatment
record of
2009)
2nd year
(treatment
record of
2008)
1st year
(treatment
record of
second half
of 2007)
Set the
disincentive
threshold
Applied
incentives
Applied
incentives and
disincentives
Incentives
1
No. of institutions
Total
AMI
C-section
Amount of money
Total
AMI
C-section
Disincentives
3
-
-
-
-
-
-
21
2
15
15
45300
31 000
14300
-
26
2
13
17
40400
25000
15400
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The CQSs of AMI care indicated improvement in all
grades (Figure 3). The mean, minimum, and maximum
values were improved and the standard deviation was
reduced. In particular, quality improvement was more
prominent in the lower grades.
II. Caesarian Section 
The results of the VIP and expanded VIP showed
continuous and marked improvement in standard scores
of the C-section rate measured between 2007 and 2010.
There was a 1.82-point decrease in the mean standard
score and a 0.64-point decrease in the standard deviation
among institutions. 
Compared to 2009, the standard scores of the C-
section rate in 2010 improved slightly, by 1.11 points. In
2010, general hospitals were included as eligible
institutions for the VIP, and in this group, there was
greater improvement (2.52 points) in the standard score.
The C-section rate standard scores of general hospitals
were lower than tertiary hospitals, suggesting that newer
participants and lower-performing institutions showed
greater improvement.
The results of the standard score of the C-section rate
showed improvement in all grades (Figure 4). The
mean, minimum, and maximum values improved and
the standard deviation was reduced. In particular,
quality improvement was more prominent in the lower
grades.
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With the demonstrated success of the VIP project, the
Ministry of Health and Welfare expanded the program in
2011 to include general hospitals (data of 2010).
However, general hospitals were excluded when their
total number of delivery cases comes to less than 200 in
C-section. Among the hospitals that treated AMI
patients in 2010, 98% of tertiary hospitals (43) and 49%
of general hospitals (71) were mandated to participate in
the Expanded VIP. For the C-section Expanded VIP, all
tertiary hospitals (44) and 46% of general hospitals (50)
participated (data of 2010).
Five performance grades were sub-divided into nine
grades. The amount of the incentive was also enlarged:
2% of the cost paid by NHIC would be provided to the
highest performing group and 1% to the second-highest
performing group (Figure 5). There were two thresholds
of penalties. For the low performers whose quality
scores were less than the upper limit of the lowest group,
a 2% penalty would be applied. For those performing
below the upper limit of the second-lowest group, a 1%
penalty would be applied. 
The expanded VIP also included a broader area of
quality assessment. Acute stroke care and prophylactic
use of antibiotics for surgical care were selected as the
next items for inclusion in the VIP. Although mortality
has steadily decreased, stroke is still the leading cause of
death, and the geographical gap in the quality of stroke
Figure 4. Improvement in composite quality scores of Caesarean section rate by year.,PSFBO7BMVF*ODFOUJWF1SPHSBN
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care is significant. Furthermore, acute stroke increases
the number of disabled persons, resulting in higher
healthcare costs. Whereas HIRA and many providers are
experienced in quality assessment and have achieved
quality improvement in general, there are non-
responding institutions with low performance despite the
quality assessment incentive and public report. To
address these challenges, the MOHW will include acute
stroke care in the VIP in May 2013.
Excessive drug utilization is one of the challenges of
Korea’s healthcare system. The irrelevant use of
antibiotics leads to resistance to antibiotics and high
surgical infection rates. The prophylactic use of
antibiotics became a pay-for-performance subject in
January 2012, and the target institutions are tertiary
hospitals and general hospitals. The details of these
issues, including the quality grades, are still under
discussion. 
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The HIRA VIP was deemed applicable to the Korea
healthcare system, but before it can be expanded further,
the program must overcome several major concerns,
outlined below.
I. Inclusion of Resource Use Measure 
The results of the HIRA VIP revealed the lack of
association between quality and low cost (Figure 6). To
move toward meeting higher quality and efficiency, the
HIRA prepared methods that adapted and applied
resource use measures to the VIP in 2011. HIRA uses
the costliness index (CI) and length of stay index (LI) as
resource use measures. The CI and LI can be calculated
after controlling the case-mix difference of each provider
within the Korean diagnosis-related group (KDRG) as
follows: 
CI=observed medical cost/expected medical cost, 
LI=observed length of stay/expected length of stay.
Utilizing the VIP, tertiary hospitals with a quality of
care below that of general hospitals, or which have costs
and/or lengths of stay above that of general hospitals,
have been targeted for improvement.
II. Rigorous Evaluation of Impact
The impact of the VIP can be seen in that variation in
quality has decreased and the mean quality has
increased. However, this has not been rigorously
evaluated, and needs further analysis for distinction from
the time trend bias.
III. Application of Value Incentive Program
to the Changing Payment System
In July 2012, the diagnosis related group (DRG)
payment system was changed from voluntary
participation to mandatory in seven DRG inpatient
Figure 5. Expanded Value Incentive Program model in Korea. 4VO.JO,JNFUBM
+1SFW.FE1VCMJD)FBMUI	

services as follow: Lens procedures, tonsillectomy
and/or adenoidectomy, appendectomy, vaginal delivery,
Caesarean section, inguinal and/or femoral hernia
procedures, anal and/or perianal procedures. as
authorized by the Health Insurance Policy Deliberation
Committee in 2011. This expansion was established
under the MOHW in accordance with the National
Health Insurance Act and the DRG payment system.
Because the VIP is a complementary payment system,
the objective and incentive structure should be
redesigned depending on the main payment system.
IV. Expansion of the Value Incentive
Program to Primary Care Clinics
While increases in national medical expenses are
mainly attributed to acute hospitals, higher-quality and
more efficient payment systems are required without
delay in primary care clinics and long-term care
facilities. If the VIP is adopted in these areas, it should
be redesigned to enhance the delivery system.
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Seven years after HIRA executed quality assessment
(2000), the HIRA VIP was established (2007) for
improving quality of care and decreasing the quality
gaps. Thus far, the VIP has targeted AMI and C-section
care. The results of the VIP showed continuous and
marked improvement in the CQSs of the AMI and C-
section measures between 2007 and 2010. Based on the
VIP’s success, the HIRA VIP was expanded to include
general hospitals. The HIRA VIP was deemed
applicable to the Korean healthcare system, but before it
can be expanded further, the program must address
several major concerns.
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